TOPLINE:

Oral lamivudine, an inflammasome inhibitor originally approved for suppressing HIV, was a relatively safe and effective treatment for improving visual acuity in adults with center-involving diabetic macular edema, a serious complication of diabetic retinopathy.

METHODOLOGY:

Researchers conducted a clinical trial to assess the effectiveness of oral lamivudine vs placebo in improving visual acuity in 24 adults (mean age, 62.7 years; 55% women) with type 2 diabetes and center-involving diabetic macular edema from a tertiary center in São Paulo, Brazil.

Best-corrected visual acuity was less than 69 letters in this cohort.

The participants were randomly assigned to receive either oral lamivudine (150 mg twice daily; 10 participants; 16 eyes) or placebo (14 participants; 21 eyes) f

See Full Page